ARGENX SE

Argenx’s VYVGART shows rapid, durable relief for MG and CIDP patients, backed by phase‑III data and FDA priority review—redefining neuromuscular treatment options.

Argenx’s sustained share‑price growth hinges on Vyvgart’s CD28 blockade, offering a targeted immunotherapy for lupus and rheumatoid arthritis that could boost investor confidence at the 2026 AGM.

Argenx’s new Phase‑3 data shows VYVGART dramatically improves ocular and generalized myasthenia gravis and expands into CIDP and CMS, offering a potent, convenient SC option with a clear regulatory roadmap.

Argenx’s VYVGART expands into ocular and seronegative myasthenia gravis, showing strong Phase‑3 data and promising CIDP results—positioning the drug for a niche, high‑value market with lower competition.

Argenx SE’s May 2026 AGM will review 2025 results and board changes, spotlighting its high‑margin specialty portfolio, digital therapy plans, and payer‑focused strategies.

Argenx SE’s 2026 AGM reveals board changes, a $25‑$30k FcRn blocker strategy, 10‑year patent window, and M&A plans to sustain growth beyond 2034 patent cliffs.

Argenx’s regulatory setbacks in Europe could slash projected revenue by 41% and erode NPV. Discover how data‑package expansion, outcome‑based pricing, and targeted M&A may salvage growth.

Argenx’s Efgarti faces regulatory delays that could push market launch 18‑24 months, but its performance‑linked pricing and RWE strategy aim to secure EU reimbursement and lift future profits.

Argenx SE to reveal new clinical data on efgartigimod for myasthenia gravis and CIDP at the 2026 AAN meeting—showcasing its antibody‑blockade platform’s potential to reshape the $3.2 bn autoimmune neurology market and impact investor outlook.

Argenx SE investor update: upcoming Q4 earnings reveal pipeline progress, regulatory milestones, and commercial strategy for autoimmune and oncology antibody therapies.